Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06952803 as recruiting, last updated 2026-09-18. Enrolment is 700 planned participants, an estimate. Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT). Primary measures include Metastasis-free survival (MFS). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, Prostate cancer.
Shares Saruparib, PARP, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/